W.G. Shaheen & Associates Dba Whitney & CO Altimmune, Inc. Call Options Transaction History

W.G. Shaheen & Associates Dba Whitney & CO

$1.05 Billion
Q3 2025

Call Options

1 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2025 Nov 07, 2025	BUY	$3.38 - $4.76 $86,190 - $121,380	25,500 New	25,500 $96,000

Others Institutions Holding ALT

# of Institutions

209

Shares Held

36.3M

Call Options Held

4.93M

Put Options Held

4.2M

Vanguard Group Inc Valley Forge, PA

6.37M
Shares

$25.1 Million
0.0% of portfolio
Black Rock Inc. New York, NY

5.32M
Shares

$21 Million
0.0% of portfolio
State Street Corp Boston, MA

2.75M
Shares

$10.8 Million
0.0% of portfolio
Tang Capital Management LLC San Diego, CA

2.75M
Shares

$10.8 Million
0.64% of portfolio
Geode Capital Management, LLC Boston, MA

1.93M
Shares

$7.62 Million
0.0% of portfolio

View Full List

About Altimmune, Inc.

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $193M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

More about ALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of W.G. Shaheen & Associates Dba Whitney & CO, based on Form 13F filings with the SEC.

News

Stay updated on W.G. Shaheen & Associates Dba Whitney & CO with notifications on news.

Account